Selumetinib

Drug Profile

Selumetinib

Alternative Names: ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Netherlands Cancer Institute; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Uveal melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thyroid cancer
  • Phase II Biliary cancer; Colorectal cancer; Neurofibromatoses; Non-small cell lung cancer
  • Phase I/II Astrocytoma; Glioma
  • Phase I Solid tumours
  • Preclinical Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Hepatocellular carcinoma; Malignant melanoma; Multiple myeloma; Uveal melanoma

Most Recent Events

  • 01 Feb 2017 The National Cancer Institute plans a phase II trial for Pancreatic cancer (Late-stage disease, Metastatic disease, Monotherapy) in USA (PO) (NCT03040986)
  • 20 Dec 2016 University of Texas M.D. Anderson Cancer Center plans a phase II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (NCT03004105)
  • 17 Nov 2016 Discontinued - Phase-III for KRAS mutation-positive Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Austria, Brazil, Canada, United Kingdom, Sweden, Italy, Israel, France, Australia, USA, Poland, Netherlands, Hungary, Germany, Spain, Romania, Belgium, Turkey, Chile, Argentina, Bulgaria, Portugal, Peru, Russia, Mexico, Ukraine (PO) because of unfavourable safety and efficacy results (before November 2016; AstraZeneca pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top